Free tool
FAERS Monitor: Ojjaara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216873 or its brand name (Ojjaara, Momelotinib Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,481
Serious
978
66% of reports
Hospitalization
349
Death reported
230
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death113
- thrombocytopenia112
- myelofibrosis96
- drug ineffective90
- anaemia86
- diarrhoea78
- pneumonia74
- fatigue72
- haemoglobin decreased66
- dizziness63
- hospitalisation63
- platelet count decreased62
- neuropathy peripheral59
- condition aggravated57
- nausea57
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 67 |
| 2024 | 381 |
| 2025 | 580 |
| 2026 | 430 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,678 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelofibrosisSignal | 96 | 465.6 | 382.4 | 42,651 |
| thrombocytopeniaSignal | 112 | 14.2 | 11.9 | 1,371 |
| haemoglobin decreasedSignal | 66 | 9.1 | 7.2 | 472 |
| neuropathy peripheralSignal | 59 | 8.8 | 6.9 | 402 |
| platelet count decreasedSignal | 62 | 8.3 | 6.5 | 390 |
| anaemiaSignal | 86 | 6.4 | 5.2 | 390 |
| hospitalisationSignal | 63 | 5.8 | 4.6 | 249 |
| pneumoniaSignal | 74 | 3.2 | 2.6 | 115 |
| condition aggravatedSignal | 57 | 2.7 | 2.1 | 58 |
| death | 113 | 1.9 | 1.6 | 46 |
| dizziness | 63 | 1.8 | 1.4 | 22 |
| diarrhoea | 78 | 1.7 | 1.4 | 23 |
| fatigue | 72 | 1.3 | 1.0 | 5 |
| nausea | 57 | 1.0 | 0.8 | 0 |
| drug ineffective | 90 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.